Low-cost therapies deliver big impact in cardiac care.
That's the conclusion of two new studies that looked at different aspects of heart disease. Both found that low-cost pharmaceutical agents offer substantial preventive impact, but both also determined that there is ample room for improvement in prescribing patterns. One other intriguing result: higher spending does not necessarily correlate with higher quality or better outcomes.